The Bayer pharmaceutical giant announced the lunar that will produce from 2022 the vaccine against coronavirus that is developing the German company CureVac.
“I would like to announce that we have the necessary capacity to produce the CureVac base based on the ARNm”, affirmed the spokesman for Bayer’s pharmaceutical sector, Stefan Oelrich, and stated that the company’s objective is to produce 160 million doses and loose primeros 12 months.
“Everything is necessary to increase the availability of vacancies”, added Oelrich.
These capacities are summed up in CureVac’s existing production of 300 million of this dose and one million million in 2022, declaration Franz-Werner Haas, Director General of CureVac, which is currently undergoing phase 3 vaccine clinicians.
Currently, “in the process of certification”, said the Minister of Health, Jens Spahn, in the press release.
The Ministry indicates that it guarantees the large-scale production of the vaccine is important in meeting the possible changes or the need for a second vaccination within one or more years.
Bayer and the CureVac laboratory, located in Tubinga, announce another association to accelerate the development of vacancies.